

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Pharmaron Beijing Co., Ltd.\***

**康龍化成(北京)新藥技術股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 3759)**

**ANNOUNCEMENT ON THE FINAL NUMBER OF  
ADDITIONAL CONVERSION SHARES TO BE ISSUED UNDER THE  
2022 CONVERTIBLE BONDS-RELATED SPECIFIC MANDATE**

References are made to the announcement of Pharmaron Beijing Co., Ltd.\* (the “**Company**”) dated March 30, 2023 and the circular of the Company dated May 25, 2023 (the “**Circular**”) in relation to, among other things, the proposed grant of the 2022 Convertible Bonds-Related Specific Mandate to issue the Additional Conversion Shares. Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Circular.

As disclosed in the Circular, the calculation of the Series 1 Bonds Further Adjusted Conversion Price, the Series 2 Bonds Further Adjusted Conversion Price and the number of Additional Conversion Shares to be allotted and issued involves exchange rate to be used to convert the Dividends from HK\$ to RMB which will be fixed at the 2022 AGM. In particular, the exchange rate to be used for calculation of the Conversion Price shall be the average of the medium rate of HK\$ to RMB announced by the People's Bank of China for five working days prior to June 21, 2023, the date on which the 2022 Profit Distribution Plan is to be considered by the Shareholders at the 2022 AGM and Class Meetings (the “**Exchange Rate**”).

Based on the Exchange Rate of HK\$1.00 to RMB0.912986, the respective final Series 1 Bonds Further Adjusted Conversion Price and the Series 2 Bonds Further Adjusted Conversion Price remain the same as those disclosed in the Circular. The Conversion Price of the Series 1 Bonds and Series 2 Bonds will be further adjusted from HK\$166.42 to HK\$110.32 and from HK\$152.32 to HK\$100.97, respectively. Assuming full conversion of the outstanding (i) Series 1 Bonds at the Series 1 Bonds Further Adjusted Conversion Price and (ii) Series 2 Bonds at the Series 2 Bonds Further Adjusted Conversion Price, the H Shares that may be convertible and issuable under the outstanding Series 1 Bonds will further increase from 13,986,540 H Shares to 21,098,984 H Shares and the H Shares that may be convertible and issuable under the outstanding Series 2 Bonds will increase from 15,274,414 H Shares to 23,043,544 H Shares. Therefore, the final number of Additional Conversion Shares under the 2022 Conversion Bond-Related Specific Mandate to be sought at the 2022 AGM will be 24,722,132 H Shares (comprising 9,840,558 H Shares and 14,881,574 H Shares that may be convertible and issuable under the outstanding Convertible Bonds as a result of the implementation of the 2021 Profit Distribution Plan and the 2022 Profit Distribution Plan, respectively).

By order of the Board  
**Pharmaron Beijing Co., Ltd.\***  
**Dr. Lou Boliang**  
*Chairman*

Beijing, the PRC  
June 20, 2023

*As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Chen Pingjin, Mr. Zhou Hongbin, Mr. Hu Baifeng and Mr. Li Jiaqing as non-executive Directors; Ms. Li Lihua, Mr. Zhou Qilin, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.*

\* *For identification purposes only*